Scientific Division

Apolipoproteins by Mass Spectrometry (WG-APO MS)

Membership

Name	Position	Country	Term	Time in Office
C. Cobbaert	Chair	NL	2nd	2020 01 - 2022 12
L.R. Ruhaak	Secretary	NL
I. Begcevic	Member
U. Ceglarek	Member	DE
V. Delatour	Member	FR
J. Dittrich	Member	DE
A. Hoofnagle	Member	US
Z. Kuklenyik	Member / CDC	US
A. Lyle	Member / CDC	US
H.W. Vesper	Member / CDC	US
H. Althaus	IVD Representative/Siemens	DE
U. Prinzing	IVD Representative/Roche	DE
E. Angles-Cano	Consultant	FR
G.M. Kostner	Consultant	AT
F. Kronenberg	Consultant	AT
L. Deprez	Consultant / JRC	BE
I. Dikaios	Consultant / JRC	BE

_________________________________________________________________________________________________

May 2021

Update on Reference Materials for Apolipoproteins and

Infographic explaining the transitioning to a new RMS for apolipoproteins:

_________________________________________________________________________________________________

April 2021

The AACC podcast on the SI-traceable RMS for standardization of serum apolipoproteins is available at following link:
https://podcasts.apple.com/us/podcast/towards-si-traceable-reference-measurement-system-for/id499883130?i=1000514846446
The associated Journal article is also available for download: https://academic.oup.com/clinchem/article/67/3/478/6040690

_________________________________________________________________________________________________

Terms of Reference

To achieve standardization of a panel of clinically relevant serum apolipoproteins (apo) A-I, B, C-I, C-II , C-III, E and apo (a) (including qualitative phenotyping where needed). Standardization is done in such a way that measurement results are traceable to SI as outlined in ISO 17511. Other traceability chains will be used in cases where traceability to SI cannot be achieved.
To evaluate clinical performance and clinical utility of serum apolipoprotein panel(s) for CVD risk stratification and treatment, in comparison to or together with contemporary blood lipids.

Current projects

Define the analytes / measurands intended to be measured.
Development of primary and secondary reference materials, including evaluation of commutability.
Development of an LC-MS/MS-based reference method for the above mentioned analytes that are unaffected by genetic variants, post-translational modifications and other factors. The reference method will meet relevant ISO standards (i.e., ISO 15195).
Evaluation of the analytical performance of the LC-MS/MS reference method.
Assessment of the performance of commercially available apolipoprotein assays compared to the reference method using commutable reference materials as well as single donation samples.
Any reference materials and reference measurement procedures developed will be submitted to JCTLM for review and listing on the JCTLM database.

Future Projects

Evaluation of clinical performance and clinical utility of the multiplexed apolipoprotein test according to the Test Evaluation framework developed by the EFLM working group on Test Evaluation (Horvath AR et al., CCA, 2014).

List of Corresponding Members, nominated by National Societies

Name	Full and Affiliate Member Societies
Sang-Guk Lee	Korean Society of Clinical Chemistry (KSCC)
Huseyin Kayadibi	Turkish Biochemical Society (TBS)

List of Corresponding Members, nominated by Corporate Members

Name	Corporate Members
Matthias Grimmler	DiaSys
Zechen Liu	MINDRAY

Working Group Chair's contact

Prof. Christa COBBAERT
Head of Department Clinical Chemistry
and Laboratory Medicine LUMC
Afd. KCL
postroute E2-P
P.O. Box 9600
2300 RC Leiden
The Netherlands
E-mail: C.M.Cobbaert@lumc.nl